RESUMEN
Bacterial resistance has become one of the most serious public health problems, globally, and drug repurposing is being investigated to speed up the identification of effective drugs. The aim of this study was to investigate the repurposing of escitalopram oxalate and clonazepam drugs individually, and in combination with the antibiotics ciprofloxacin and sulfamethoxazole-trimethoprim, to treat multidrug-resistant (MDR) microorganisms and to evaluate the potential chemical nuclease activity. The minimum inhibitory concentration, minimum bactericidal concentration, fractional inhibitory concentration index, and tolerance level were determined for each microorganism tested. In vitro antibacterial activity was evaluated against 47 multidrug-resistant clinical isolates and 11 standard bacterial strains from the American Type Culture Collection. Escitalopram oxalate was mainly active against Gram-positive bacteria, and clonazepam was active against both Gram-positive and Gram-negative bacteria. When associated with the two antibiotics mentioned, they had a significant synergistic effect. Clonazepam cleaved plasmid DNA, and the mechanisms involved were oxidative and hydrolytic. These results indicate the potential for repurposing these non-antibiotic drugs to treat bacterial infections. However, further studies on the mechanism of action of these drugs should be performed to ensure their safe use.
Asunto(s)
Ciprofloxacina , Bacterias Gramnegativas , Antibacterianos/farmacología , Ciprofloxacina/farmacología , Citalopram/farmacología , Clonazepam/farmacología , ADN , Reposicionamiento de Medicamentos , Farmacorresistencia Bacteriana Múltiple , Bacterias Grampositivas , Humanos , Pruebas de Sensibilidad Microbiana , Plásmidos/genética , Sulfametoxazol/farmacología , Trimetoprim/farmacologíaRESUMEN
Benzodiazepines (BZDs) produce versatile pharmacological actions through positive modulation of GABAA receptors (GABAARs). A previous study has demonstrated that high concentrations of diazepam potentiate GABA currents on the α1ß2γ2 and α1ß2 GABAARs in a flumazenil-insensitive manner. In this study, the high-concentration effects of BZDs and their sensitivity to flumazenil were determined on synaptic (α1ß2γ2, α2ß2γ2, α5ß2γ2) and extra-synaptic (α4ß2δ) GABAARs using the voltage-clamp electrophysiology technique. The in vivo evaluation of flumazenil-insensitive BZD effects was conducted in mice via the loss of righting reflex (LORR) test. Diazepam induced biphasic potentiation on the α1ß2γ2, α2ß2γ2 and α5ß2γ2 GABAARs, but did not affect the α4ß2δ receptor. In contrast to the nanomolar component of potentiation, the second potentiation elicited by micromolar diazepam was insensitive to flumazenil. Midazolam, clonazepam, and lorazepam at 200 µM exhibited similar flumazenil-insensitive effects on the α1ß2γ2, α2ß2γ2 and α5ß2γ2 receptors, whereas the potentiation induced by 200 µM zolpidem or triazolam was abolished by flumazenil. Both the GABAAR antagonist pentylenetetrazol and Fa173, a proposed transmembrane site antagonist, abolished the potentiation induced by 200 µM diazepam. Consistent with the in vitro results, flumazenil antagonized the zolpidem-induced LORR, but not that induced by diazepam or midazolam. Pentylenetetrazol and Fa173 antagonized the diazepam-induced LORR. These findings support the existence of non-classical BZD binding sites on certain GABAAR subtypes and indicate that the flumazenil-insensitive effects depend on the chemical structures of BZD ligands.
Asunto(s)
Benzodiazepinas/farmacología , Flumazenil/farmacología , Receptores de GABA-A/metabolismo , Animales , Animales no Consanguíneos , Clonazepam/farmacología , Diazepam/farmacología , Femenino , Antagonistas del GABA/farmacología , Masculino , Ratones , Midazolam/farmacología , Xenopus laevis/metabolismo , Ácido gamma-Aminobutírico/metabolismoRESUMEN
Anxiety disorders are highly prevalent and considered a major public health concern worldwide. Current anxiolytics are of limited efficacy and associated with various side effects. Our novel herbal treatment (NHT), composed of four constituents, was shown to reduce anxiety-like behavior while precluding a common side effect caused by current anxiolytics, i.e., sexual dysfunction. Nevertheless, NHT's mechanism of action is yet to be determined. There is evidence that some medicinal herbs interact with the GABAergic system. Therefore, we aimed to examine whether NHT's anxiolytic-like effect is exerted by alterations in GABAA receptor density in the hippocampus, prefrontal cortex, and hypothalamus. The effects of 3-weeks treatment with NHT on anxiety-like behavior and locomotion were assessed using the elevated plus maze (EPM) and the open field test (OFT), respectively. Regional GABAA receptor levels were analyzed using [3H] RO15-1788 high-affinity binding assays. In stressed mice, NHT reduced anxiety-like behavior similarly to the benzodiazepine, clonazepam, while locomotion remained intact. Lack of changes or minor changes in regional GABAA receptor density in the brain were induced by NHT or clonazepam. In naive mice, performance in the EPM, locomotion and GABAA receptor densities were not altered by treatment with NHT or clonazepam. These findings support NHT as an efficacious and safe anxiolytic, although the GABAergic involvement remains to be further elucidated.
Asunto(s)
Ansiolíticos/farmacología , Ansiedad/tratamiento farmacológico , Encéfalo/metabolismo , Extractos Vegetales/farmacología , Receptores de GABA-A/metabolismo , Animales , Ansiolíticos/uso terapéutico , Ansiedad/metabolismo , Encéfalo/efectos de los fármacos , Clonazepam/farmacología , Clonazepam/uso terapéutico , Masculino , Aprendizaje por Laberinto , Ratones , Ratones Endogámicos C57BL , Extractos Vegetales/uso terapéutico , Receptores de GABA-A/genéticaRESUMEN
Secondary paroxysmal dyskinesias (SPDs) are short, episodic, and recurrent movement disorders, classically related to multiple sclerosis (MS). Carbamazepine is effective, but with risk of adverse reactions. We identified 7 patients with SPD among 457 MS patients (1.53%). SPD occurred in face ( n = 1), leg ( n = 2), or arm +leg ( n = 4) several times during the day. Magnetic resonance imaging (MRI) showed new or enhancing lesions in thalamus ( n = 1), mesencephalic tegmentum ( n = 1), and cerebellar peduncles ( n = 5). Patients were treated with clonazepam and then acetazolamide ( n = 1), acetazolamide ( n = 5), or levetiracetam ( n = 1) with response within hours (acetazolamide) to days (levetiracetam). No recurrences or adverse events were reported after a median follow-up of 33 months.
Asunto(s)
Anticonvulsivantes/farmacología , Cerebelo/diagnóstico por imagen , Discinesias , Distonía , Esclerosis Múltiple , Tegmento Mesencefálico/diagnóstico por imagen , Tálamo/diagnóstico por imagen , Acetazolamida/farmacología , Adulto , Anticonvulsivantes/administración & dosificación , Clonazepam/farmacología , Discinesias/diagnóstico por imagen , Discinesias/tratamiento farmacológico , Discinesias/etiología , Discinesias/fisiopatología , Distonía/diagnóstico por imagen , Distonía/tratamiento farmacológico , Distonía/etiología , Distonía/fisiopatología , Femenino , Estudios de Seguimiento , Humanos , Levetiracetam , Imagen por Resonancia Magnética , Masculino , Esclerosis Múltiple/complicaciones , Esclerosis Múltiple/diagnóstico por imagen , Esclerosis Múltiple/fisiopatología , Piracetam/análogos & derivados , Piracetam/farmacología , Resultado del TratamientoRESUMEN
AIM: The present study was aimed at investigating the effect of trans-6-(4-chlorobutyl)-5-hydroxy-4-(phenylthio)-1-tosyl-5,6-dihydropyridine-2(1H)-one (HTDP-2), a novel synthetic compound, on the release of endogenous glutamate in rat cerebrocortical nerve terminals (synaptosomes) and exploring the possible mechanism. METHODS: The release of glutamate was evoked by the K⺠channel blocker 4-aminopyridine (4-AP) and measured by an on-line enzyme-coupled fluorimetric assay. We also used a membrane potential-sensitive dye to assay nerve terminal excitability and depolarization, and a Ca²âº indicator, Fura-2-acetoxymethyl ester, to monitor cytosolic Ca²âº concentrations ([Ca²âº](c)). RESULTS: HTDP-2 inhibited the release of glutamate evoked by 4-AP in a concentration-dependent manner. Inhibition of glutamate release by HTDP-2 was prevented by the chelating intraterminal Ca²âº ions, and by the vesicular transporter inhibitor bafilomycin A1, but was insensitive to the glutamate transporter inhibitor DL-threo-ß-benzyloxyaspartate. HTDP-2 did not alter the resting synaptosomal membrane potential or 4-AP-mediated depolarization whereas it decreased the 4-AP-induced increase in [Ca²âº](c). Furthermore, the inhibitory effect of HTDP-2 on the evoked glutamate release was abolished by the N-, and P/Q-type Ca²âº channel blocker ω-conotoxin MVIIC, but not by the ryanodine receptor blocker dantrolene, or the mitochondrial Naâº/Ca²âº exchanger blocker CGP37157. CONCLUSION: Based on these results, we suggest that, in rat cerebrocortical nerve terminals, HTDP-2 decreases voltage-dependent Ca²âº channel activity and, in so doing, inhibits the evoked glutamate release.
Asunto(s)
Bloqueadores de los Canales de Calcio/farmacología , Canales de Calcio/fisiología , Corteza Cerebral/fisiología , Ácido Glutámico/fisiología , Fármacos Neuroprotectores/farmacología , Piridonas/farmacología , Compuestos de Tosilo/farmacología , 4-Aminopiridina/farmacología , Sistema de Transporte de Aminoácidos X-AG/metabolismo , Animales , Calcio/análisis , Calcio/fisiología , Bloqueadores de los Canales de Calcio/síntesis química , Bloqueadores de los Canales de Calcio/toxicidad , Canales de Calcio/metabolismo , Clonazepam/análogos & derivados , Clonazepam/farmacología , Citosol/fisiología , Dantroleno/farmacología , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Interacciones Farmacológicas , Ácido Glutámico/análisis , Ácido Glutámico/toxicidad , Masculino , Potenciales de la Membrana , Terminaciones Nerviosas/fisiología , Fármacos Neuroprotectores/síntesis química , Fármacos Neuroprotectores/toxicidad , Bloqueadores de los Canales de Potasio/farmacología , Piridonas/síntesis química , Piridonas/toxicidad , Ratas , Ratas Sprague-Dawley , Inhibidores del Simportador de Cloruro Sódico y Cloruro Potásico/farmacología , Sinaptosomas/fisiología , Tiazepinas/farmacología , Compuestos de Tosilo/síntesis química , Compuestos de Tosilo/toxicidadRESUMEN
ETHNOPHARMACOLOGICAL RELEVANCE: Sonchus oleraceus L. has been used as a general tonic in Brazilian folk medicine. Nevertheless, available scientific information regarding this species is scarce; there are no reports related to its possible effect on the central nervous system. AIM OF THE STUDY: This study was conducted to establish the anxiolytic effect of extracts from the aerial parts of Sonchus oleraceus. MATERIALS AND METHODS: This study evaluated the effect of hydroethanolic and dichloromethane extracts of Sonchus oleraceus in mice submitted to the elevated plus-maze and open-field tests. Clonazepam was used as the standard drug. RESULTS: In the elevated plus-maze test, the Sonchus oleraceus extracts increased the percentage of open arm entries (P<0.05) and time spent in the open-arm portions of the maze (P<0.05). The extracts induce an anti-thigmotactic effect, evidenced by increased locomotor activity into the central part of the open field set-up (P<0.05). The extracts administered at 30-300 mg/kg, p.o. had a similar anxiolytic effect to clonazepam (0.5 mg/kg, p.o.). CONCLUSION: These data indicate that Sonchus oleraceus extract exerts an anxiolytic-like effect on mice.
Asunto(s)
Ansiolíticos/uso terapéutico , Ansiedad/tratamiento farmacológico , Actividad Motora/efectos de los fármacos , Fitoterapia , Extractos Vegetales/uso terapéutico , Sonchus , Animales , Ansiolíticos/farmacología , Clonazepam/farmacología , Clonazepam/uso terapéutico , Masculino , Aprendizaje por Laberinto , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos ICR , Componentes Aéreos de las Plantas , Extractos Vegetales/farmacologíaRESUMEN
The antischistosomal activity of clonazepam, when administered alone or in association with oxamniquine and praziquantel, was experimentally evaluated in mice infected with Schistosoma mansoni. The animals were treated 45 days post-infection with a single dose, by oral route, according to three treatment schedules: clonazepam 25 mg/kg and sacrificed 15 min, 1h or 4 h after treatment; clonazepam 1.0, 2.5 or 10.0 mg/kg and sacrificed 15 days post-treatment or with the dose of 10 mg/kg in association with oxamniquine 50 mg/kg or praziquantel 200 mg/kg, single dose, orally, every schedule with a control group. The efficacy of the drugs in vivo was assessed by means of worm counts and their distribution in mesentery and liver, mortality and oogram changes. In the chemotherapeutic schedules used, clonazepam did not present antischistosomal activity and the result of the association of this drug with oxamniquine or praziquantel was not significantly different from the one obtained when these two last drugs were administered alone. In the in vitro experiments, the worms exposed to 0.6 mg/mL clonazepam remained motionless throughout the 8-day-period of observation, without egg-laying, whereas the worms of the control group showed normal movements, egg-laying and hatching of miracidia on the last day of observation. The results obtained in the present study confirm the action of clonazepam on S. mansoni adult worm, in vitro, causing total paralysis of males and females. However, no additive or synergistic effects were observed when clonazepam were used in association with oxamniquine or praziquantel.
Asunto(s)
Animales , Femenino , Masculino , Ratones , Clonazepam/farmacología , Schistosoma mansoni/efectos de los fármacos , Esquistosomiasis mansoni/tratamiento farmacológico , Esquistosomicidas/farmacología , Clonazepam/administración & dosificación , Evaluación Preclínica de Medicamentos , Quimioterapia Combinada , Hígado/parasitología , Mesenterio/parasitología , Oxamniquina/administración & dosificación , Oxamniquina/farmacología , Praziquantel/administración & dosificación , Praziquantel/farmacología , Esquistosomicidas/administración & dosificación , Factores de TiempoRESUMEN
The antischistosomal activity of clonazepam, when administered alone or in association with oxamniquine and praziquantel, was experimentally evaluated in mice infected with Schistosoma mansoni. The animals were treated 45 days post-infection with a single dose, by oral route, according to three treatment schedules: clonazepam 25 mg/kg and sacrificed 15 min, 1h or 4 h after treatment; clonazepam 1.0, 2.5 or 10.0 mg/kg and sacrificed 15 days post-treatment or with the dose of 10 mg/kg in association with oxamniquine 50 mg/kg or praziquantel 200 mg/kg, single dose, orally, every schedule with a control group. The efficacy of the drugs in vivo was assessed by means of worm counts and their distribution in mesentery and liver, mortality and oogram changes. In the chemotherapeutic schedules used, clonazepam did not present antischistosomal activity and the result of the association of this drug with oxamniquine or praziquantel was not significantly different from the one obtained when these two last drugs were administered alone. In the in vitro experiments, the worms exposed to 0.6 mg/mL clonazepam remained motionless throughout the 8-day-period of observation, without egg-laying, whereas the worms of the control group showed normal movements, egg-laying and hatching of miracidia on the last day of observation. The results obtained in the present study confirm the action of clonazepam on S. mansoni adult worm, in vitro, causing total paralysis of males and females. However, no additive or synergistic effects were observed when clonazepam were used in association with oxamniquine or praziquantel.
Asunto(s)
Clonazepam/farmacología , Schistosoma mansoni/efectos de los fármacos , Esquistosomiasis mansoni/tratamiento farmacológico , Esquistosomicidas/farmacología , Animales , Clonazepam/administración & dosificación , Evaluación Preclínica de Medicamentos , Quimioterapia Combinada , Femenino , Hígado/parasitología , Masculino , Mesenterio/parasitología , Ratones , Oxamniquina/administración & dosificación , Oxamniquina/farmacología , Praziquantel/administración & dosificación , Praziquantel/farmacología , Esquistosomicidas/administración & dosificación , Factores de TiempoRESUMEN
The influence of stresses of various etiology (prolonged isolation, inescapable electrostimulation) on the antiaggressive effect of anxiolytics was studied in outbread white male rats. It was established that, in contrast to the anticonflict effect (decreasing under the action of stress), then antiaggressive action of the drugs studied (diazepam, phenazepam, clonazepam, alprazolam) exhibits qualitative changes. In the absence of stress, the threshold of aggressive reaction is low and anxiolytics increase this level. Under the action of stress, the threshold of aggressive reaction increases, and the same drugs reduce this threshold to the normal level, thus producing proaggressive action. The degree of changes and the rate of restoration of the initial activity depend on the efficacy of anxiolytics, the strength and duration of stress, and on the duration of drug administration during the stress aftereffect. A possible mechanism of this phenomenon can be the interaction of the GABA-benzodiazepine and opiate endogenous systems.
Asunto(s)
Agresión/efectos de los fármacos , Ansiolíticos/farmacología , Estrés Fisiológico/psicología , Agresión/fisiología , Alprazolam/farmacología , Animales , Animales no Consanguíneos , Conducta Animal/efectos de los fármacos , Benzodiazepinas/farmacología , Clonazepam/farmacología , Diazepam/farmacología , Masculino , Umbral del Dolor/efectos de los fármacos , RatasRESUMEN
Mutations in GABA-A receptor subunits have been reported in a number of idiopathic generalized epilepsies including childhood absence epilepsy. One of these mutations is located within a high-affinity benzodiazepine-binding domain, and clonazepam is clinically used as an anti-absence drug. The intrathalamic loop consisting of the GABAergic neurons of the nucleus reticularis thalami (NRT) and the thalamocortical (TC) neurons of sensory thalamic nuclei plays an essential role in spike and wave discharges. In a well-established genetic model of absence epilepsy (Genetic Absence Epilepsy rat from Strasbourg, GAERS), systemic injections of benzodiazepines have been shown to suppress spike-and-waves discharges. The aim of this study, therefore, was to determine whether the sensitivity of GABAergic synaptic currents to clonazepam in NRT and TC neurons was different in GAERS and non-epileptic control (NEC) rats. In both pre-seizure GAERS and NEC clonazepam (100 nM) had no effect on the mIPSCs recorded from TC neurons while it increased the decay time constant of the mIPSCs recorded in NRT neurons by a similar amount in GAERS (54.5+/-5%) and NEC (50.7+/-5%). Similar results have been obtained in the presence of 100 microM Cd2+, showing that the effect of clonazepam did not occur via modulation of voltage-activated Ca2+ currents. These results are relevant to understand that in GAERS, the clonazepam anti-absence actions cannot be fully explained by the enhancement of the intra-NRT inhibition and the modulation of the GABAergic synaptic currents in other brain areas, in particular the cortex, must be taken into consideration.
Asunto(s)
Anticonvulsivantes/farmacología , Clonazepam/farmacología , Epilepsia Tipo Ausencia/patología , Neuronas/efectos de los fármacos , Tálamo/patología , Ácido gamma-Aminobutírico/metabolismo , 2-Amino-5-fosfonovalerato/farmacología , 6-Ciano 7-nitroquinoxalina 2,3-diona/farmacología , Potenciales de Acción/efectos de los fármacos , Potenciales de Acción/fisiología , Animales , Anticonvulsivantes/uso terapéutico , Cadmio/farmacología , Clonazepam/uso terapéutico , Modelos Animales de Enfermedad , Interacciones Farmacológicas , Estimulación Eléctrica/métodos , Epilepsia Tipo Ausencia/tratamiento farmacológico , Epilepsia Tipo Ausencia/genética , Antagonistas de Aminoácidos Excitadores/farmacología , Femenino , Técnicas In Vitro , Masculino , Inhibición Neural/efectos de los fármacos , Inhibición Neural/fisiología , Neuronas/fisiología , Técnicas de Placa-Clamp/métodos , Ratas , Ratas Mutantes , Sinapsis/efectos de los fármacosRESUMEN
Networks of interconnected inhibitory neurons, such as the thalamic reticular nucleus (TRN), often regulate neural oscillations. Thalamic circuits generate sleep spindles and may contribute to some forms of generalized absence epilepsy, yet the exact role of inhibitory connections within the TRN remains controversial. Here, by using mutant mice in which the thalamic effects of the anti-absence drug clonazepam (CZP) are restricted to either relay or reticular nuclei, we show that the enhancement of intra-TRN inhibition is both necessary and sufficient for CZP to suppress evoked oscillations in thalamic slices. Extracellular and intracellular recordings show that CZP specifically suppresses spikes that occur during bursts of synchronous firing, and this suppression grows over the course of an oscillation, ultimately shortening that oscillation. These results not only identify a particular anatomical and molecular target for anti-absence drug design, but also elucidate a specific dynamic mechanism by which inhibitory networks control neural oscillations.
Asunto(s)
Relojes Biológicos/fisiología , Neuronas/fisiología , Receptores de GABA-A/metabolismo , Tálamo/fisiología , Potenciales de Acción/efectos de los fármacos , Potenciales de Acción/fisiología , Animales , Relojes Biológicos/efectos de los fármacos , Clonazepam/farmacología , Estimulación Eléctrica , Moduladores del GABA/farmacología , Técnicas In Vitro , Ratones , Ratones Mutantes , Red Nerviosa/fisiología , Inhibición Neural/efectos de los fármacos , Inhibición Neural/fisiología , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Subunidades de Proteína/efectos de los fármacos , Subunidades de Proteína/genética , Subunidades de Proteína/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores de GABA-A/efectos de los fármacos , Receptores de GABA-A/genética , Núcleos Talámicos/efectos de los fármacos , Núcleos Talámicos/fisiología , Tálamo/citología , Tálamo/efectos de los fármacosRESUMEN
Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both seizure and afterdischarge durations. The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test. However, only two first combinations occurred to be of pharmacodynamic nature. Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate. On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam. The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.
Asunto(s)
Amígdala del Cerebelo/efectos de los fármacos , Convulsivantes/efectos adversos , Combinación de Medicamentos , Excitación Neurológica/efectos de los fármacos , Triazoles/antagonistas & inhibidores , Triazoles/uso terapéutico , Ácido 3-piridinacarboxílico, 1,4-dihidro-2,6-dimetil-5-nitro-4-(2-(trifluorometil)fenil)-, Éster Metílico/farmacología , Aminofilina/administración & dosificación , Aminofilina/efectos adversos , Aminofilina/farmacocinética , Amígdala del Cerebelo/fisiopatología , Amígdala del Cerebelo/cirugía , Animales , Bicuculina/administración & dosificación , Bicuculina/efectos adversos , Bicuculina/farmacocinética , Carbamazepina/farmacología , Clonazepam/antagonistas & inhibidores , Clonazepam/farmacología , Convulsivantes/administración & dosificación , Convulsivantes/antagonistas & inhibidores , Modelos Animales de Enfermedad , Interacciones Farmacológicas , Electrodos Implantados , Inyecciones Intraperitoneales , Ácido Kaínico/administración & dosificación , Ácido Kaínico/farmacocinética , Masculino , N-Metilaspartato/administración & dosificación , N-Metilaspartato/efectos adversos , N-Metilaspartato/farmacocinética , Ratas , Ratas Wistar , Convulsiones/inducido químicamente , Convulsiones/fisiopatología , Convulsiones/prevención & control , Técnicas Estereotáxicas , Estricnina/administración & dosificación , Estricnina/efectos adversos , Estricnina/farmacocinética , Factores de Tiempo , Triazoles/administración & dosificación , Ácido Valproico/administración & dosificación , Ácido Valproico/antagonistas & inhibidores , Ácido Valproico/farmacocinéticaRESUMEN
During HIV-1 encephalitis, the chemotaxis-inducing activity of Tat may enhance the viral life cycle through recruitment of additional susceptible microglial cells to foci of infection. Benzodiazepines (BDZs) readily penetrate the blood-brain barrier and are known to possess anti-inflammatory properties. Pretreatment of human microglial cells with peripheral (Ro5-4864) and mixed (diazepam), but not central (clonazepam), benzodiazepine receptor ligands was found to potently suppress HIV-1 Tat-induced chemotaxis. Application of Tat to microglial cells evokes an increase in intracellular calcium concentration ([Ca(2+)]i) that rapidly desensitizes the cells. Diazepam's inhibitory effect was associated with its ability to block Tat-induced [Ca(2+)]i mobilization. These data support the notion that through their effects on microglia, peripheral BDZ receptor ligands could alter the neuropathogenesis of HIV-1.
Asunto(s)
Adyuvantes Inmunológicos/farmacología , Señalización del Calcio/efectos de los fármacos , Quimiotaxis/efectos de los fármacos , Diazepam/farmacología , Productos del Gen tat/antagonistas & inhibidores , VIH-1/efectos de los fármacos , Microglía/efectos de los fármacos , Proteínas del Tejido Nervioso/efectos de los fármacos , Receptores de GABA-A/efectos de los fármacos , Benzodiazepinonas/farmacología , Clonazepam/farmacología , Productos del Gen tat/fisiología , Humanos , Microglía/virología , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/fisiología , Receptores CCR5/biosíntesis , Receptores CCR5/genética , Receptores de GABA-A/fisiología , Regulación hacia Arriba/efectos de los fármacos , Productos del Gen tat del Virus de la Inmunodeficiencia HumanaRESUMEN
This study examined the behavioral effects of agents active at the gamma-aminobutyric acid (GABA(A)) receptor complex in the mouse staircase paradigm. The neuroactivesteroids dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S) were compared with the benzodiazepine agonist clonazepam, the non-benzodiazepine hypnotic compound zopiclone, and the antiepileptic agent gabapentin. Clonazepam, zopiclone and gabapentin reduced rearing activity at doses that did not affect climbing. The rearing-suppression effect of clonazepam and zopiclone, but not of gabapentin, was blocked by the benzodiazepine antagonist flumazenil, suggesting that the added effect of gabapentin is not mediated by the benzodiazepine receptor on the GABA complex. DHEA suppressed rearing behavior at doses that did not reduce climbing, but analysis with the Bonferroni post hoc test yielded no statistically significant difference. This inhibitory effect was attenuated by flumazenil. By contrast, DHEA-S suppressed, in a dose-dependent manner, both rearing and climbing behavior to the same extent. The findings support the potential value of the mouse staircase paradigm for demonstrating behaviorally relevant anxiolysis of test compounds shown to interact in vitro with the GABA(A) receptor complex.
Asunto(s)
Aminas , Ansiedad/tratamiento farmacológico , Conducta Animal/efectos de los fármacos , Ácidos Ciclohexanocarboxílicos , Conducta Exploratoria/efectos de los fármacos , Actividad Motora/efectos de los fármacos , Receptores de GABA-A/efectos de los fármacos , Ácido gamma-Aminobutírico/metabolismo , Acetatos , Adyuvantes Inmunológicos/farmacología , Animales , Ansiolíticos/farmacología , Ansiedad/fisiopatología , Compuestos de Azabiciclo , Conducta Animal/fisiología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Clonazepam/farmacología , Deshidroepiandrosterona/farmacología , Sulfato de Deshidroepiandrosterona/farmacología , Relación Dosis-Respuesta a Droga , Conducta Exploratoria/fisiología , Flumazenil/farmacología , Moduladores del GABA/farmacología , Gabapentina , Hipnóticos y Sedantes/farmacología , Masculino , Ratones , Ratones Endogámicos ICR , Actividad Motora/fisiología , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Piperazinas/farmacología , Receptores de GABA-A/metabolismoRESUMEN
Rasmussen's encephalitis (RE) is a progressive, rare childhood disease characterized by severe epilepsy, hemiplegia, dementia, and inflammation of the brain. While one mechanism underlying the pathogenesis of RE has been hypothesized to be mediated by production of excitotoxic GluR3 autoantibodies to the AMPA receptor, other neuropathological etiologies have also been indicated. Whole-cell patch clamp recordings of GABA(A) receptor mediated responses were conducted in neurons acutely isolated from an RE patient, and compared to properties of non-focal human temporal cortical neurons. RE neurons appeared similar anatomically to control cortical neurons. Significant differences in GABAergic responses were evident between RE and control neurons. GABA was significantly more potent in RE than in control cortical neurons (EC50 of 13 microM vs 23 microM, respectively). In addition, the overall efficacy of GABA was significantly decreased in RE neurons, associated with a decrease in postsynaptic GABA current density in RE neurons (5.1 pA/microm2) in comparison to controls (9.2 pA/microm2). Augmentation of GABA responses by the benzodiazepine, clonazepam (CNZ), was significantly reduced in RE in comparison to control neurons (34% vs 99% augmentation at 100 nM). The RE-associated reduced functional efficacy and altered pharmacology of neuronal GABA(A) receptors is consistent with overall disinhibition in RE neurons, and could contribute to the generation of the severe epileptic activity evident in this disorder.
Asunto(s)
Corteza Cerebral/citología , Encefalitis/fisiopatología , Lóbulo Frontal/citología , Lóbulo Frontal/fisiopatología , Neurotransmisores/metabolismo , Neurotransmisores/fisiología , Técnicas de Placa-Clamp , Tamaño de la Célula , Células Cultivadas , Niño , Enfermedad Crónica , Clonazepam/farmacología , Relación Dosis-Respuesta a Droga , Encefalitis/patología , Epilepsias Parciales/fisiopatología , Femenino , Lóbulo Frontal/cirugía , Lateralidad Funcional/fisiología , Moduladores del GABA , Humanos , Imagen por Resonancia Magnética , Potenciales de la Membrana/efectos de los fármacos , Células Piramidales/citología , Células Piramidales/efectos de los fármacos , Células Piramidales/fisiología , Receptores de GABA-A/efectos de los fármacos , Receptores de GABA-A/fisiología , Ácido gamma-Aminobutírico/farmacologíaRESUMEN
In the thalamus, paradoxical changes in response to augmentation of inhibition can occur as a result of either cellular or network effects. Clonazepam, a GABA(A) agonist, produces a paradoxical reduction in evoked thalamocortical neuron inhibitory postsynaptic potential (IPSP) in thalamic slice. This has been hypothesized to be a result of augmentation in inhibitory to inhibitory connections. In a computer model, orthodromic simulation produced an increase in initial IPSP, a result contrary to that found experimentally. This failure was traced to the inability of orthodromic activation to produce fast enough recurrent inhibition to alter initial reticularis neuron firing. Simulated antidromic stimulation was able to reduce this initial spike train and reproduced the experimental finding.
Asunto(s)
Clonazepam/farmacología , Moduladores del GABA/farmacología , Tálamo/efectos de los fármacos , Animales , Estimulación Eléctrica , Modelos Neurológicos , Vías Nerviosas/efectos de los fármacos , Vías Nerviosas/fisiología , Ratas , Receptores de GABA-A/efectos de los fármacos , Receptores de GABA-B/efectos de los fármacos , Sinapsis/fisiologíaRESUMEN
1. Nucleus reticularis thalami (NRT) is a nucleus composed entirely of GABAergic neurons, which functions as a pacemaker to synchronize thalamocortical oscillations. To study the functional properties of GABAergic inhibition mediated through activation of gamma-aminobuturic acid-A (GABAA) receptors in these cells, neurons were isolated acutely from NRT at various postnatal developmental stages and recorded from using whole cell patch-clamp techniques. 2. Application of GABA to NRT neurons elicited a large, bicuculline sensitive current with an average reversal potential of -60.6 +/- 1.9 mV (mean +/- SD) in postnatal day (p) 19-21 neurons and -51.2 +/- 3.1 mV in p7 neurons, presumably mediated through activation of a GABAA-mediated chloride conductance. The potency of GABA in activating GABAA receptors decreased significantly with postnatal development in NRT neurons and was best fitted with EC50s of 24.9, 33.9, and 67.2 microM, in neurons isolated from p5-9, p18-25, and p58-74 rats, respectively. The density of GABAA receptors in the membranes of NRT neurons increased significantly with postnatal development. In addition, the GABA current decay rate slowed significantly in neurons isolated from older animals relative to early postnatal rat pups. 3. Both the potency and efficacy of benzodiazepine augmentation of GABAA responses in NRT neurons increased significantly with development. The EC50 of clonazepam decreased from 26 to 6 nM in p5-9 and p58-74 NRT neurons, respectively, whereas the efficacy increased from 126 to 163% augmentation over the same developmental range. 4. The elevated efficacy of clonazepam (CNZ) in NRT neurons relative to thalamic and cortical neurons, particularly in neurons isolated from adult (> p58) rats, is consistent with the anticonvulsant profile of this drug in controlling Generalized Absence epilepsy. Augmenting inhibition within NRT would enhance NRT/ NRT inhibitory connections and thereby decrease the amplitude of NRT-mediated synchronizing inhibitory postsynaptic potentials onto thalamus (where CNZ has low efficacy), in turn making it more difficult to elicit burst firing in thalamus due to deinactivation and subsequent activation of the low-threshold Ca2+ current. 5. The present developmental profile of GABAA responses in GABAergic NRT neurons provides data important in understanding the role of GABAergic inhibition within NRT in the modulation of normal and pathological thalamocortical rhythms in the brain and is also relevant in understanding potential differences in GABAA receptor physiology and pharmacology in GABAergic interneurons relative to glutamatergic neurons.
Asunto(s)
Envejecimiento/fisiología , Moduladores del GABA/farmacología , Neuronas/fisiología , Receptores de GABA-A/fisiología , Formación Reticular/fisiología , Tálamo/fisiología , Ácido gamma-Aminobutírico/fisiología , Envejecimiento/patología , Análisis de Varianza , Animales , Canales de Cloruro/efectos de los fármacos , Clonazepam/farmacología , Inhibición Neural/efectos de los fármacos , Inhibición Neural/fisiología , Neuronas/efectos de los fármacos , Técnicas de Placa-Clamp , Ratas , Receptores de GABA-A/efectos de los fármacos , Formación Reticular/citología , Formación Reticular/efectos de los fármacos , Tálamo/citología , Tálamo/efectos de los fármacosRESUMEN
The development of tolerance to the anticonvulsant effects of clonazepam, clobazam, and diazepam were studied in genetically epilepsy-prone rats following intraperitoneal (IP) or oral administration. The anticonvulsant effects were evaluated on seizures evoked by means of auditory stimulation (109 dB, 12-16 kHz). All compounds showed 60 min after IP injection antiseizure activity with ED50 against clonus of 0.24 mumol kg-1 for clonazepam, 0.72 mumol kg-1 for diazepam, and 3.9 mumol kg-1 for clobazam. After 120 min of oral administration the ED50 against clonus of 2.37 mumol kg-1 for clonazepam, 15.8 mumol kg-1 for diazepam, and 30 mumol kg-1 for clobazam. The dose chosen for the chronic treatment were 2.5 mumol kg-1 for clonazepam, 15 mumol kg-1 for diazepam, and 30 mumol kg-1 for clobazam. The animals were treated three times daily for 4 or 6 weeks. Auditory stimulation was administered 60 min after drug IP injection on various days. During treatment, tolerance was observed as a loss of drug anticonvulsant effects. No changes of occurrence of audiogenic seizures was observed in rats treated with vehicle. Tolerance to the anticonvulsant activity developed most rapidly during clobazam treatment, less rapidly following diazepam treatment, and most slowly during clonazepam treatment. Sixty minutes after IP injection on various days of chronic treatment the motor impairment induced by these benzodiazepines was also studied by means of a rotarod apparatus. The tolerance to the motor impairment developed more rapidly than the anticonvulsant effects. The response to auditory stimulation to benzodiazepines was stopped 24 and 48 h after chronic treatment with these compounds, showing no residual drug effects and that rats were still tolerant. The genetically epilepsy-prone rats is a reliable and sensitive model for studying long-term effects of anticonvulsant drugs.
Asunto(s)
Ansiolíticos , Anticonvulsivantes/farmacología , Benzodiazepinas/farmacología , Epilepsia/genética , Estimulación Acústica , Administración Oral , Animales , Anticonvulsivantes/administración & dosificación , Benzodiazepinas/administración & dosificación , Benzodiazepinonas/administración & dosificación , Benzodiazepinonas/farmacología , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Clobazam , Clonazepam/administración & dosificación , Clonazepam/farmacología , Diazepam/administración & dosificación , Diazepam/farmacología , Relación Dosis-Respuesta a Droga , Tolerancia a Medicamentos , Epilepsia/tratamiento farmacológico , Femenino , Inyecciones Intraperitoneales , Masculino , Actividad Motora/efectos de los fármacos , Equilibrio Postural/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Receptores de GABA-A/efectos de los fármacos , Receptores de GABA-A/metabolismoRESUMEN
Recent investigations in the authors' laboratory have shown that acute tone exposure (4 kHz continuous tone, 104 dB sound pressure level (SPL), 30-min duration) induces increases in the amplitude of click-evoked potentials in the inferior colliculus (IC). These increases have been attributed to a decrease in GABAA-mediated inhibition on IC neurons. In the present study, we examined the effects of three compounds (diazepam, clonazepam, and (-)-baclofen) that are known to enhance GABAergic inhibition on these tone exposure-induced increases and on changes in temporal integration in the IC. (-)-Baclofen was the only one of the three compounds tested that reversed in a dose-dependent manner the effects of tone exposure on both the amplitude of the click-evoked potentials recorded from the IC and on measures of the changes in temporal integration based on these potentials. Diazepam and clonazepam exhibited remarkably different effects on the click-evoked potentials recorded from the surface of the IC. Diazepam caused a dose-dependent decrease in one of the components of the IC potentials that reflects postsynaptic activity in the IC, whereas clonazepam caused a dose-dependent decrease in a peak that reflects input to the IC from the superior olivary complex (SOC). At dosages up to 40 mg/kg, neither diazepam nor clonazepam reversed the changes in temporal integration in the IC that were induced by the tone exposure; diazepam caused a small, but statistically significant, enhancement of the effects of tone exposure on this function. The results of this study show that (-)-baclofen is a potent modulator of both the excitability of neurons in the ascending auditory pathway and the processing of auditory information by IC neurons. The finding of the present study that two benzodiazepines (clonazepam and diazepam) have remarkably different effects on evoked potentials, which reflects both input to the IC and postsynaptic events in the IC neurons, suggests heterogenicity of the GABAA receptor from one structure to another in the ascending auditory pathway. We suggest that (-)-baclofen may be clinically useful in treating disorders of the auditory system that are caused by plasticity in the ascending auditory pathway.
Asunto(s)
Moduladores del GABA/farmacología , Colículos Inferiores/efectos de los fármacos , Relajantes Musculares Centrales/farmacología , Acúfeno/tratamiento farmacológico , Estimulación Acústica , Animales , Umbral Auditivo/efectos de los fármacos , Baclofeno/farmacología , Baclofeno/uso terapéutico , Clonazepam/farmacología , Clonazepam/uso terapéutico , Diazepam/farmacología , Diazepam/uso terapéutico , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Potenciales Evocados Auditivos del Tronco Encefálico/efectos de los fármacos , Femenino , Moduladores del GABA/uso terapéutico , Colículos Inferiores/citología , Relajantes Musculares Centrales/uso terapéutico , Plasticidad Neuronal/efectos de los fármacos , Neuronas/citología , Neuronas/efectos de los fármacos , Núcleo Olivar/efectos de los fármacos , Ratas , Ratas Wistar , EstereoisomerismoRESUMEN
Spontaneous thalamocortical epileptiform activity was elicited in rodent thalamocortical slices by a medium containing no added Mg2+. Multiple varieties of activity were generated in these slices, including simple thalamocortical burst complex (sTBC) activity that resembled the spike-wave discharges of generalized absence epilepsy, and complex thalamocortical burst complex (cTBC) activity that resembled generalized tonic-clonic seizure discharges. In a further pharmacological characterization of this activity, the effects of the broad-spectrum anticonvulsants valproic acid, alpha-methyl-alpha-phenylsuccinimide (the active metabolite of methsuximide) and clonazepam were studied. All three drugs were found to be effective in controlling both sTBC and cTBC activity when applied in clinically relevant concentration ranges. The effectiveness of valproic acid against spontaneous rhythms in vitro was not due to augmentation of GABAergic inhibition. No effect of valproic acid on GABA-activated chloride currents was evident in patch-clamp recordings of acutely isolated thalamic or cortical neurons. The equivalent general clinical and experimental spectrum of action of broadly effective anticonvulsants provided an additional correlation between the clinical efficacy of anticonvulsant drugs and their effects against epileptiform discharges in rodent thalamocortical slices. This further validates spontaneous generalized low-Mg2+ thalamocortical activity as a potentially valuable in vitro model of the primary generalized epilepsies, in which the cellular mechanisms underlying generation and control of these seizure discharges can be studied.